Omnicell Inc. (OMCL) Receives “Outperform” Rating from Oppenheimer Holdings Inc.

omnicell-inc-omcl-receives-8220outperform8221-rating-from-oppenheimer-holdings-inc.jpg

Omnicell Inc. (NASDAQ:OMCL)‘s stock had its “outperform” rating reiterated by equities research analysts at Oppenheimer Holdings Inc. in a research report issued on Tuesday. They presently have a $46.00 price target on the stock. Oppenheimer Holdings Inc.’s price objective would indicate a potential upside of 20.70% from the company’s previous close.
Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Omnicell from a “hold” rating to a “strong-buy” rating and set a $41.00 target price on the stock in a research note on Monday, July 11th. FBR & Co upped their price target on shares of Omnicell from $40.00 to $41.00 and gave the company an “outperform” rating in a research report on Friday, July 29th. Finally, Sidoti lowered shares of Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 price target for the company. in a research report on Thursday, September 8th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Omnicell currently has an average rating of “Buy” and a consensus target price of $38.13.
Shares of Omnicell (NASDAQ:OMCL) traded down 0.45% during midday trading on Tuesday, reaching $37.94. 31,372 shares of the company’s stock traded hands. The firm has a market capitalization of $1.37 billion, a PE ratio of 96.29 and a beta of 0.69. The stock’s 50-day moving average price is $37.71 and its 200 day moving average price is $32.65. Omnicell has a one year low of $25.06 and a one year high of $40.50.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/13/omnicell-inc-omcl-receives-outperform-rating-from-oppenheimer-holdings-inc.html

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 28th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.32 by $0.06. The business had revenue of $175.60 million for the quarter, compared to analysts’ expectations of $170.89 million. Omnicell had a net margin of 2.36% and a return on equity of 10.41%. The business’s revenue for the quarter was up 55.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.28 EPS. On average, equities research analysts expect that Omnicell will post $1.58 earnings per share for the current fiscal year.
In other Omnicell news, Director Gary S. Petersmeyer sold 2,400 shares of the stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $39.39, for a total transaction of $94,536.00. Following the completion of the sale, the director now directly owns 17,987 shares of the company’s stock, valued at approximately $708,507.93. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Robin Gene Seim sold 3,645 shares of the stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $35.00, for a total transaction of $127,575.00. Following the sale, the executive vice president now directly owns 55,420 shares of the company’s stock, valued at $1,939,700. The disclosure for this sale can be found here. 3.75% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. Conestoga Capital Advisors LLC raised its stake in shares of Omnicell by 29.8% in the first quarter. Conestoga Capital Advisors LLC now owns 1,742,769 shares of the company’s stock worth $48,571,000 after buying an additional 400,400 shares during the period. Norges Bank bought a new stake in shares of Omnicell during the fourth quarter worth about $11,096,000. Riverhead Capital Management LLC raised its stake in shares of Omnicell by 2,518.0% in the second quarter. Riverhead Capital Management LLC now owns 285,890 shares of the company’s stock worth $23,298,000 after buying an additional 274,970 shares during the period. Glenmede Trust Co. NA raised its stake in shares of Omnicell by 31.5% in the first quarter. Glenmede Trust Co. NA now owns 1,011,363 shares of the company’s stock worth $28,185,000 after buying an additional 242,052 shares during the period. Finally, Westfield Capital Management Co. LP bought a new stake in shares of Omnicell during the second quarter worth about $8,190,000. 95.26% of the stock is owned by institutional investors and hedge funds.
About Omnicell
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

Receive News & Ratings for Omnicell Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Omnicell Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Omnicell Inc. (OMCL) Receives “Outperform” Rating from Oppenheimer Holdings Inc."

Leave a comment

Your email address will not be published.

*